Moti Ramgopal, MD

Consultant Physician/Director Associates in Infectious Diseases
Midway Immunology and Research Center
Fort Pierce, FL

Disclosure: AbbVie: Speaker's Bureau
Allergan: Speaker's Bureau
Gilead: Advisor or Review Panel member, Speaker's Bureau
Insamed: Speaker's Bureau
Janssen: Advisor or Review Panel member, Speaker's Bureau
Merck: Advisor or Review Panel member
ViiV: Advisor or Review Panel member, Speaker's Bureau

Presentation(s):

• 887 - High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

  Thursday, October 3
  4:15 PM – 4:30 PM